CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 90 enrolled
Drug / intervention
Platelet Poor Plasma (PPP) +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01812564
NCT01812564Phase 2Completed
CompareCT.gov

Clinical Utilization of Growth Factors Preparations in the Management of Acute Hamstring Muscle Strain Injury

Aspetar·interventional·Posted Mar 18, 2013·Updated Jan 14, 2015

In Brief

A Phase 2 clinical trial evaluating Platelet Poor Plasma (PPP) and Platelet Rich Plasma (PRP) for Acute Hamstring Muscle Strain Injury. Completed, enrolled 90 participants across 1 site.

Detailed Summary

The purpose of this study is to evaluate the therapeutic benefit of utilizing complex growth factor preparations (Platelet Rich Plasma (PRP) in the management of acute hamstring injuries. The hypothesis is that the time to return to sport is shorter in the patient group treated with Complex Growth Factor Preparations (PRP) in combination with exercise therapy in comparison with 2 control groups: * the patient group treated with Platelet Poor Plasma (PPP) injections in combination with exercise therapy (control injection AND usual care). * the patient group treated with exercise therapy (usual care)

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcute Hamstring Muscle Strain Injury
CountriesQatar
Collaborators--

Timeline

Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedMar 18, 2013
Enrollment StartNov 1, 2009
Primary CompletionOct 1, 2013
Study CompletionOct 1, 2014
TodayJul 2, 2026
Enrollment to primary: 3.9 yearsPosted 13.3 years ago

Interventions

Platelet Poor Plasma (PPP)biological

Platelet Rich Plasma (PRP)biological